Showing results (521-530 of 561) with videos related to
Sort By:
Pageof 57
The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.Cancer Discovery|May 15, 2016
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialAlex Pearson, Elizabeth Smyth, Irina S Babina, et al.Nature Cancer|February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2019
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric CancerFilippo Pietrantonio, Rosalba Miceli, Alessandra Raimondi, et al.Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2025
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled AnalysisAlessandra Raimondi, Gabriele Tinè, Alexej Ballhausen, et al.Microbiome|May 9, 2023
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancerJames L Alexander, Joram M Posma, Alasdair Scott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.Pageof 57